SmartHarvest Portfolios LLC Has $1.65 Million Holdings in AbbVie Inc. $ABBV

SmartHarvest Portfolios LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 23.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,603 shares of the company’s stock after selling 2,324 shares during the quarter. AbbVie accounts for about 0.7% of SmartHarvest Portfolios LLC’s portfolio, making the stock its 20th largest holding. SmartHarvest Portfolios LLC’s holdings in AbbVie were worth $1,653,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Chelsea Counsel Co. acquired a new stake in AbbVie during the third quarter worth approximately $26,000. Litman Gregory Wealth Management LLC acquired a new position in AbbVie in the fourth quarter valued at about $28,000. Imprint Wealth LLC lifted its position in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the period. Westend Capital Management LLC acquired a new stake in AbbVie during the fourth quarter worth about $29,000. Finally, IFC & Insurance Marketing Inc. acquired a new stake in AbbVie during the fourth quarter worth about $31,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of AbbVie stock opened at $251.52 on Friday. The stock’s 50-day moving average is $215.16 and its 200 day moving average is $219.18. AbbVie Inc. has a one year low of $181.73 and a one year high of $253.35. The firm has a market cap of $444.38 billion, a price-to-earnings ratio of 123.90, a PEG ratio of 0.74 and a beta of 0.32.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same period in the previous year, the company posted $2.46 earnings per share. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. On average, sell-side analysts expect that AbbVie Inc. will post 14.28 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said the FDA approved Skyrizi for pediatric use in psoriatic disease, making it the first and only IL-23 inhibitor in the U.S. approved for children six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. The expansion broadens the drug’s addressable market and supports long-term sales growth. Article: SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
• Positive Sentiment: AbbVie’s Apogee Therapeutics acquisition is being viewed favorably by analysts, with Canaccord raising its price target and saying the deal strengthens AbbVie’s long-term growth outlook by adding promising pipeline assets. Article: AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
• Positive Sentiment: AbbVie is also benefiting from broader healthcare sector strength, with shares hitting new highs as investors rotate into defensive large-cap pharma names. Article: Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
• Neutral Sentiment: AbbVie announced it will host its second-quarter 2026 earnings call on July 31, which is a standard investor update and does not by itself change fundamentals. Article: AbbVie to Host Second-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Commentary pieces also highlighted AbbVie’s recent pediatric label expansions in Europe for Skyrizi and Maviret, reinforcing the company’s shift toward earlier-disease and younger-patient growth opportunities. Article: Will AbbVie’s (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?

Wall Street Analyst Weigh In

ABBV has been the subject of several analyst reports. DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Guggenheim reiterated a “buy” rating and set a $249.00 price objective on shares of AbbVie in a research report on Friday, May 1st. Wells Fargo & Company set a $260.00 price objective on shares of AbbVie in a research note on Monday. Finally, Evercore set a $235.00 target price on shares of AbbVie in a research report on Friday, May 15th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $253.81.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.